Back to news
Global rollout of HIV prevention drug lenacapavir faces access challenges in Uganda
ONE REPORT·Published ·Event date ·Main source · Africanews
Story essentials
Gilead Sciences, Global Fund, PEPFAR, Action for Improved Health and Wealth
Uganda
September 2026
Original reports
Lenacapavir, a twice-a-year HIV prevention shot, is being deployed globally but faces shortages in regions like Mbarara, Uganda.
Funding cuts for community-based organizations have hindered HIV testing and outreach services.
Global Fund and PEPFAR aim to provide lenacapavir to 3 million people by 2028.
Generic supply is expected to scale up by late 2026 and become widely available in 2027.
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRead next
Prioritized by shared people, places, and events.
Global markets react to AI funding concerns and geopolitical tensions
Global tech shares faced a rout due to AI funding concerns. Oil prices reached a five-month peak following Houthi attacks and Middle East tensions. Markets are paring back bets on interest-rate hikes.